股价下跌后，Deliverx削减德意志银行股份

2026-08-24 23:15

Deutsche Bank downgraded Argenx (ARGX) to hold from buy saying that the stock has had a nice run since it was upgraded in March and recent positive phase 3 results for Vyvgart (efgartigimod alfa) in autoimmune myositis were largely accounted for.
The bank did raise the target price to €925 from €900 (~7% upside based on Monday's trading price on the Euronext Brussels exchange).
Emmanuel Papadakis said that while he had already assumed Vyvgart success for autoimmune myositis, he is slightly raising his peak sales estimate to $14B ($1.5B from the myositis indication).
In the pipeline, Papadakis highlighted empasiprubart, in phase 3 for the rare muscle movement disorder multifocal motor neuropathy. While he is optimistic for the EMPASSION trial, "we view it as both riskier and more consequential for sentiment than numbers, which doesn't provide a particularly compelling reason to keep adding at these levels."

More on argenx SE